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ABSTRACT
Objectives: Management of anticoagulated patients
after head injury is unclear due to lack of robust
evidence. This study aimed to determine the adverse
outcome rate in these patients and identify risk factors
associated with poor outcome.
Design: Multicentre, observational study using routine
patient records.
Setting: 33 emergency departments in England and
Scotland.
Participants: 3566 adults (aged ≥16 years) who had
suffered blunt head injury and were currently taking
warfarin.
Main outcome measures: Primary outcome
measure was rate of adverse outcome defined as death
or neurosurgery following initial injury, clinically
significant CT scan finding or reattendance with related
complication within 10 weeks of initial hospital
attendance. Secondary objectives included identifying
risk factors for adverse outcome using univariable and
multivariable analyses.
Results: Clinical data available for 3534/3566 patients
(99.1%), median age 79 years; mean initial
international normalised ratio (INR) 2.67 (SD 1.34);
81.2% Glasgow Coma Scale (GCS) 15: 59.8% received
a CT scan with significant head injury-related finding in
5.4% (n=208); 0.5% underwent neurosurgery; 1.2%
patients suffered a head injury-related death. Overall
adverse outcome rate was 5.9% (95% CI 5.2% to
6.7%). Patients with GCS=15 and no associated
symptoms had lowest risk of adverse outcome (risk
2.7%; 95% CI 2.1 to 3.6). Patients with GCS=15
multivariable analysis (using imputation) found risk of
adverse outcome to increase when reporting at least
one associated symptom: vomiting (relative risk (RR)
1.8; 95% CI 1.0 to 3.4), amnesia (RR 3.5; 95% CI 2.1
to 5.7), headache (RR 1.3; 95% CI 0.8 to 2.2), loss of
consciousness (RR 1.75; 95% CI 1.0 to 3.0). INR
measurement did not predict adverse outcome in
patients with GCS=15 (RR 1.1; 95% CI 1.0 to 1.2).
Conclusions: In alert warfarinised patients following
head injury, the presence of symptoms is associated
with greater risk of adverse outcome. Those with
GCS=15 and no symptoms are a substantial group and
have a low risk of adverse outcome.
Trial registration number: NCT02461498.
BACKGROUND
With over one million attendances reported
in the UK and the USA annually, head injury
is one of the most common injuries present-
ing to the emergency department (ED).1–4
Furthermore, up to 2.4% of the adult popu-
lation of England per year are reportedly
taking anticoagulation therapy,5 of which,
warfarin is currently the most widely pre-
scribed. These patients tend to be elderly
and have comorbidities increasing their risk
of falls and subsequent head injury. The
management of anticoagulated patients fol-
lowing head injury therefore presents a sub-
stantial clinical challenge in an expanding
and important group of patients.
Prior to January 2014, head injury guid-
ance from the UK National Institute for
Health and Care Excellence (NICE) did not
speciﬁcally focus on managing patients
receiving anticoagulation6 and current prac-
tice throughout England in the management
of these patients varies considerably.7 This is
also reﬂected in international guidelines for
head injury produced in Scotland,8 Canada9
and USA,10 among others,11–14 where there
is variation, largely due to the lack of a
Strengths and limitations of this study
▪ This study is the largest to date that has identi-
fied and followed up the outcomes of 3534
patients taking warfarin who suffer head injury.
▪ Routinely available data from patient records
were used thus missing data in some variables
ranges from 9% to 42%. Owing to the known
issues with using routine medical data, a strat-
egy was employed to improve accuracy and min-
imise inconsistencies, as well as follow-up of
missing data with hospital sites up to 10 weeks
following initial hospital attendance.
▪ Missing data issues were handled by using mul-
tiple imputation in order to undertake the ana-
lysis for risk factors.
Mason S, et al. BMJ Open 2017;7:e014324. doi:10.1136/bmjopen-2016-014324 1
Open Access Research
substantive evidence base to guide best practice. The
uncertainty regarding the appropriate management of
anticoagulated patients following an injury to the head,
particularly relates to the use of CT,15–21 the value of
measuring the international normalised ratio (INR),22 23
and the need for hospital admission.18 21 24 To date
there has been one adequately powered study of this
group of patients,17 thus the risk of serious intracranial
bleeding, adverse neurological outcome and death is
uncertain. Previous studies of anticoagulated patients
with head injury have identiﬁed the risk of subsequent
intracranial bleeding to be between 5.1% and
7.8%,17 25 26 with other studies calculating an OR of
between 2.73 and 5.48 for the same outcome compared
with non-anticoagulated patients.16 27 All of these studies
also demonstrated wide variation in the investigation,
admission and subsequent management of anticoagula-
tion for these patients.
METHODS
Setting and participants
We undertook an observational study across 33 hospital
sites in England and Scotland. Adults (≥16 years)
attending the ED in a participating hospital site between
September 2011 and March 2013 presenting with head
trauma who were currently taking warfarin were
included.
We deﬁned head trauma as any non-penetrating head
injury above the neck irrespective of mechanism.28
Patients experiencing multisystem trauma were included
in the study. We excluded patients with a penetrating
injury or head trauma following a spontaneous intracra-
nial event.
Data collection
Research staff within the hospital sites identiﬁed con-
secutive patients from all attendances at the respective
ED and recorded basic demographic information,
attendance details, injury mechanism and clinical exam-
ination data from using routinely available medical
records. The latter included initial documented Glasgow
Coma Scale (GCS), other physiological observations,
symptoms and evidence of trauma, and results of any
investigations, all collected via a standardised study web-
based data form. Investigations were undertaken accord-
ing to perceived clinical need and no additional investi-
gations were mandated as part of the study. To minimise
missing data, inconsistencies and improve accuracy, a
strategy was employed for reviewing patient medical
records (see online supplementary table S1),29 as well as
follow-up with research staff up to 10 weeks after initial
attendance. CT scan reports were retrospectively
reviewed by an independent expert clinical working
group and a preagreed classiﬁcation assigned to the
ﬁndings. The expert clinical working group were ﬁve
emergency medicine consultants who had access to
same information as ED clinicians at the hospital site
(the investigative data—observation and blood results)
in order to facilitate classifying any abnormalities
reported on the CT scan. The classiﬁcation (table 1) was
developed speciﬁcally for the study and agreed by the
expert working group and the study steering committee,
prior to any reviewing.
Based on 381 CT scans reviewed by ﬁve reviewers—
Krippendorff’s α=0.816 (95% CI 0.765 to 0.862) suggest-
ing good degree of reliability.30
Every effort was made to identify consecutive eligible
patients in order to minimise missing eligible patients
through reviewing patient attendances with head injury,
those taking warfarin, and also by checking which
patients received a head CT, or had their INR checked.
Ethical approval for the study was obtained and an
‘opt-out’ method was adopted where patients were
informed of their inclusion in the study on receipt of a
study pack containing information about the study and
how to ‘opt-out’. This was mailed to the patient’s home
address 6 weeks after attendance. Patients identiﬁed as
still being admitted to the hospital at this point were
contacted directly by the hospital research nurse.
The study aimed to determine the rate of adverse
outcome associated with head injury. The primary
outcome of interest was the rate of adverse outcome
deﬁned by death or neurosurgery resulting from the
initial injury, a clinically signiﬁcant CT scan ﬁnding (clas-
siﬁcation 1 from table 1) or reattendance to the hospital
with a signiﬁcant head injury-related complication up to
10 weeks after the original attendance. Identifying risk
factors for adverse outcome was a secondary objective.
Sample size
The study was powered to detect a clinically important
relative risk of 2 for up to 10 potential clinical risk
factors. Assuming the population risk is 5%, 3000
patients would result in 150 cases. This number of cases
(and the same number of controls) would correspond
to 80% power at the (Bonferroni corrected) 0.5% level
to detect a risk factor with a 20% frequency in controls.
Assuming the true risk is 5%, the sample size of 3000
would give a precise estimate of the population risk
where the expected 95% CI would have a width of
0.016.
Table 1 CT scan classification
Classification Description
1 Intracranial abnormality likely to be due to
injury (eg, subdural, extradural,
contusion, etc)
2 Other abnormality likely to be due to
injury (eg, scalp haematoma,
uncomplicated fracture, etc)
3 Other abnormality unlikely to be due to
injury
4 Normal CT scan
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Statistical methods and data analyses
All analyses were conducted using Stata V.13. The study
was a closed cohort design and hence risks and relative
risks could be reported. Clustering within the 33 EDs
was allowed for in the analysis by using multilevel
Poisson regression with robust SE estimation. All
reported relative risks and 95% CIs have been adjusted
for the clustering by ED. Non-comparative proportions
and risks and their 95% CIs are reported without adjust-
ing for clustering. The primary outcome for the statis-
tical analysis was an adverse outcome related to the head
injury.
At the study planning stage we set a Bonferroni cor-
rected signiﬁcance threshold of 0.005 to allow for the
multiple testing for up to 10 risk factors. However, rather
than making this a formal adjustment we have reported
the nominal p values and unadjusted 95% CIs. We have
considered GCS as a categorical variable with four levels
(GCS=15, GCS=14, GCS=13, GCS<13), INR as both a
numerical and binary variable, and four binary neuro-
logical symptoms.
Multiple imputation for missing data was performed
using the Realcom software (http://www.bristol.ac.uk/
cmm/software/realcom/). This software supports mul-
tiple imputation using chained equations and allows for
multilevel or clustered data. The variables included in
the multiple imputation (which was limited to partici-
pants with GCS=15) were adverse outcome (primary
outcome), age, gender, log(INR), the four neurological
symptoms (headache, vomiting, amnesia and loss of con-
sciousness; secondary outcomes) and the hospital ED.
This generated 100 imputed data sets which were then
analysed in Stata V.13 using Rubin’s combination rules
to form one set of results.31
RESULTS
Over the 19-month period, 3566 patients were enrolled
in the study excluding 154 patients that requested they
be withdrawn. Anonymised clinical data were submitted
for nearly all patients (99%, n=3534).
Of the 3534 included patients, the age range was 18–
101 years (median 79 years; IQR=12) with the majority
arriving by ambulance (73.8%, n=2607) and presenting
following a fall (91.6%, n=3238). The most common pre-
senting diagnosis recorded in 91.4% (n=3229) was head
wound (table 2).
Over two-thirds (68.7%, n=2428) of patients did not
have any associated head injury symptoms reported
(amnesia, vomiting, loss of consciousness or headache).
On initial evaluation in the ED, 81.2% (n=2871) patients
had a GCS score of 15 and 60 (1.7%) patients had a
GCS of 12 or lower, indicating moderate-to-severe head
injury. INR was measured in 83% (n=2934) of patients
and the median value was 2.4 (IQR=1.9–3.0), with less
than one-third of patients having a measurement
outside of the normal therapeutic range (INR=2–4)32
(INR<2: 21.0%, n=741; INR>4: 7.1%, n=252). Overall,
59.8% of patients (n=2114) received a CT scan which
was consistent with a classiﬁcation 1 complication in
5.4% (n=192).
Other adverse outcomes included neurosurgery in
0.5% (n=18) patients, a related head injury reattendance
in 1.0% (n=37), and a head injury-related death in 1.2%
(n=41). This produced an overall adverse outcome rate
for the whole cohort of 5.9% (n=208, 95% CI 5.2 to
6.7). The adverse outcome rate included patients only
once irrespective of whether they experienced multiple
adverse outcomes.
Risk factors for adverse outcome
The variables considered as potential risk factors in the
univariable analysis were GCS, INR, vomiting, amnesia,
loss of consciousness and headache with age and sex as
potential confounders. The aim of this analysis was to
identify predictors of adverse outcome to assist in clin-
ical decision-making. All of these variables (except for
age and sex) were found to be statistically signiﬁcant at
the 5% level in a univariable analysis.
Glasgow Coma Scale
GCS was recorded for 3229 patients (91.4%). While GCS
was the strongest predictor of risk, we found patients
presented with a GCS below 15 rarely (11.1%, n=358).
We therefore considered this risk factor alone. The
lowest risk is for those with GCS=15 (table 3), with
GCS<15 being a strong risk factor. Three hundred and
ﬁve patients did not have a recorded GCS, although
their risk of adverse outcome was lower and not signiﬁ-
cantly different to the GCS=15 group.
International normalised ratio
INR was recorded in 2934 patients (n=522 not per-
formed at site and n=78 missing). The median INR in
those with an adverse outcome is slightly higher than
those without an adverse outcome (2.5 vs 2.4; ﬁgure 1).
Univariable Poisson regression found the continuous
variable INR was statistically signiﬁcantly positively asso-
ciated with a higher risk of adverse outcome (p=0.029).
However, this association reduced (relative risk=1.11,
95% CI 0.95 to 1.18, p=0.298) when patients with GCS
below 15 were excluded. The risk of adverse outcome in
those 600 patients with INR missing was 2.0% (95% CI
1.14% to 3.49%).
Neurological symptoms
We considered each of the neurological symptoms:
amnesia; vomiting; headache and loss of consciousness
in all patients, and then in patients with GCS=15 only
(table 4). There were missing values for each of the
symptoms (table 2).
Patients with GCS=15 and no reported symptoms
accounted for a signiﬁcant proportion of the cohort
(55.8%, n=1973) and had the lowest risk of an adverse
outcome (risk 2.7%, 95% CI 2.1 to 3.6). The group of
Mason S, et al. BMJ Open 2017;7:e014324. doi:10.1136/bmjopen-2016-014324 3
Open Access
Table 2 Patient demographics
All patients Missing data
n (%) N (%)
Total 3534
Gender 0
Males 1738 (49.2)
Age group, years 0
<60 251 (7.1)
60–69 313 (8.9)
70–79 925 (26.2)
80–89 1674 (47.4)
90+ 371 (10.5)
Symptoms, type
Amnesia 341 (9.6) 1464 (41.4)
Vomiting 163 (4.6) 900 (25.5)
Loss of consciousness 425 (12.0) 620 (17.5)
Headache 535 (15.1) 1511 (42.8)
Number of symptoms 0
0 2428 (68.7)
1 824 (23.3)
2+ 282 (8.0)
Admitted 0
Yes 2216 (62.7)
Length of stay, days 0
0 341 (9.6)
1–2 975 (27.6)
3–10 413 (11.7)
11+ 487 (13.8)
Glasgow Coma Scale 0
15 2871 (81.2)
14 275 (7.8)
13 23 (0.7)
<13 60 (1.7)
Not recorded at site 305 (8.6)
INR 78 (2.2)
<2 741 (21.0)
2–4 1941 (54.9)
>4 252 (7.1)
Not performed at site 522 (14.8)
CT scan performed 0
Yes 2114 (59.8)
Time to scan (from ED attendance) 195 (5.5)
<1 hour 199 (9.4)
1–4 hours 1210 (57.2)
4+ hours 610 (28.9)
CT grading 135 (3.8)
Intracranial abnormality likely to be due to injury 192 (5.4)
Other abnormality likely to be due to injury (eg, scalp haematoma, uncomplicated fracture) 417 (11.8)
Other abnormality unlikely to be due to injury 909 (25.7)
Normal CT scan 461 (13.0)
Reversal therapy 179 (5.1)
Yes 189 (5.3)
Prothrombin complex 30 (0.8)
Intravenous vitamin K 100 (2.8)
Oral vitamin K 16 (0.5)
Other* 42 (1.2)
Neurosurgical procedures 36 (1.0)
Yes 18 (0.5)
Further hospital attendances 0
Head injury-related to original attendance 37 (1.0)
Continued
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1973 patients where no symptom was reported as
present included a substantial number of patients where
at least one symptom report was missing or not recorded
(n=1171). In those patients with no missing data for
symptoms, this risk was further reduced (n=802, risk
2.1%, 95% CI 1.3 to 3.4). Each of the symptom variables
was statistically signiﬁcantly associated with increased
risk of an adverse outcome. With the exception of
the symptom headache, the associations remained
statistically signiﬁcant after the exclusion of patients with
GCS below 15.
In univariable analyses for each symptom the risk of
an adverse outcome was statistically signiﬁcantly raised
when the symptom was missing (compared with those
with no symptom present). In general, single symptoms
were more likely to be missing if there was at least one
positive symptom reported. The patterns of missing data
suggest that an analysis limited to the complete records
Table 3 Univariable analysis of GCS
GCS value Patients n
Adverse
outcome n (%)
Relative risk * (compared
with GCS=15) 95% CI* p Value
15 2871 124 (4.3) 1 NA
14 275 37 (13.4) 3.11 2.20 to 4.41 <0.001
13 23 9 (39.1) 8.79 5.37 to 14.37 <0.001
12 and below 60 29 (48.3) 10.53 7.90 to 15.36 <0.001
Below 15 358 75 (20.9) 4.82 3.66 to 6.35 <0.001
GCS missing 305 9 (3.0) 0.65 0.34 to 1.39 0.296
*Relative risks and 95% CIs estimated using multilevel Poisson regression to allow for clustering by hospital site.
GCS, Glasgow Coma Scale; NA, not available.
Figure 1 Box and Whisker plot
of log(INR) by adverse outcome.
INR, international normalised
ratio.
Table 2 Continued
All patients Missing data
n (%) N (%)
Died 0
Yes 249 (7.0)
Head injury-related 41 (1.2)
Other 158 (4.5)
Not known 50 (1.4)
Overall adverse outcome rate 208 (5.9)
*Included combinations of reversal therapy given (prothrombin complex+vitamin K=38; prothrombin complex+vitamin K+platelets+tranexamic
acid=1; fresh frozen plasma+vitamin K+platelets=1) and vitamin K (intravenous or oral not known)=1.
ED, emergency department; INR, international normalised ratio.
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may not be representative of the full cohort and we may
obtain biased results when attempting to ﬁt multivari-
able models. We therefore used multiple imputation to
impute values for the four neurological symptoms in
those patients with GCS=15.
The univariable analysis shows a similar pattern to that
found in table 4 for those with GCS=15. However, follow-
ing the imputation the symptom headache is now statis-
tically signiﬁcant at the 5% level. The multiple
imputation permitted a full multivariable model to be
ﬁtted to examine joint associations (table 5). When all
four symptoms are included in the same model amnesia
is the strongest predictor with vomiting or loss of con-
sciousness associated with slightly lower relative risks and
headache associated with the lowest relative risk. It
should be noted that the baseline reference group in
the joint analysis is the group of patients with no symp-
toms reported. In the joint analysis only two of these
symptoms are statistically signiﬁcant; however, all the
95% CIs include the relative risk of 2 suggesting that all
four symptoms may have important clinical signiﬁcance.
The analysis following multiple imputation assumes that
all these neurological symptoms are measurable which
may not be the case (eg, headache is subjective).
However, the analysis following imputation provides a
means to assess how the presence of up to four symp-
toms contributes to overall risk.
Missing data
Missing data have been considered throughout the statis-
tical analysis, examining the risk in those with missing
data on a variable by variable basis. The missing data in
the reporting of neurological symptoms was clearly an
important issue, with headache and amnesia being most
commonly missing. These are symptoms that would be
more difﬁcult for an observer to report than a patient.
There may be good clinical reason why some symptoms
cannot be reported such as older patients with pre-
existing memory problems not being able to report
amnesia. It is of some concern that around one-third of
the data cannot be assessed for presence of a neuro-
logical symptom. Hence, we cannot be conﬁdent that
data are missing at random. Assuming that the data are
missing at random we have used a multiple imputation
approach to allow us to examine how the risk factors
may act together.
DISCUSSION
The overall risk of adverse outcome in the cohort was
5.9%. The study has shown that patients with a GCS of
15 accounted for a signiﬁcant proportion of the study
cohort (88.9%) and that in those with no associated
neurological symptoms, the risk of adverse outcome is
low (2.7%), with risk increasing as neurological symp-
toms increase and GCS falls (see box 1). The
Table 4 Univariable analysis results grouped by neurological symptoms category
Symptom Patients Non-missing, n
Risk in those
symptom positive,
% (95% CI)
Risk in those
symptom negative,
% (95% CI)
Relative
risk* 95% CI p Value
Vomiting All 2634 15.95 (9.51 to 9.67) 4.05 (3.34 to 4.90) 3.94 2.32 to 6.70 <0.001
GCS=15
only
2237 9.84 (5.65 to 16.56) 3.26 (2.58 to 4.11) 3.00 1.68 to 5.41 0.001
Amnesia All 2070 14.96 (11.54 to 19.16) 3.47 (2.70 to 4.43) 4.37 3.05 to 6.25 <0.001
GCS=15
only
1796 14.07 (10.36 to 18.83) 2.87 (2.14 to 3.84) 4.90 3.34 to 7.19 <0.001
Headache All 2023 7.66 (5.69 to 10.25) 3.63 (2.79 to 4.71) 2.11 1.33 to 3.34 0.001
GCS=15
only
1723 5.64 (3.87 to 8.15) 3.17 (2.33 to 4.30) 1.78 0.97 to 3.26 0.062
LOC† All 2914 14.82 (11.75 to 18.53) 3.58 (2.91 to 4.38) 4.14 2.92 to 5.88 <0.001
GCS=15
only
2475 10.48 (7.61 to 14.26) 2.99 (2.35 to 3.80) 3.50 2.26 to 5.41 <0.001
*Compared with no symptoms.
†LOC=loss of consciousness.
GCS, Glasgow Coma Scale.
Table 5 Relative risk in patients GCS=15 associated with
neurological symptoms following multiple imputation
(n=2871)
Neurological
symptom
Relative
risk* 95% CI p Value
Univariable analysis
Amnesia 4.83 3.22 to 7.23 <0.001
LOC† 3.49 2.30 to 9.95 <0.001
Vomiting 3.00 1.66 to 5.24 <0.001
Headache 1.75 1.04 to 2.84 0.016
Multivariable joint analysis
Amnesia 3.48 2.13 to 5.70 <0.001
Vomiting 1.80 0.97 to 3.36 0.063
LOC† 1.75 1.03 to 2.99 0.039
Headache 1.30 0.76 to 2.22 0.331
*Compared with no symptoms.
†LOC=loss of consciousness.
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multivariable analysis found that in patients with
GCS=15, while all four neurological symptoms are
important in terms of increasing the risk of adverse
outcome, only amnesia and loss of consciousness
reached statistical signiﬁcance. INR, a controversial
measurement often used as a guide in the management
of patients’ care, was found to show no association with
adverse outcome once other risk factors are included.
This study is the largest of its kind with sufﬁcient
power to describe the outcomes of a cohort of anticoa-
gulated head injury patients presenting to the ED, and
their predictors for an adverse outcome. The adverse
outcomes we have described are comparable with those
presented in some previous studies that also report on
complication rates for anticoagulated patients separ-
ately.17 25 However, other studies have reported much
higher incidences of complications among this popula-
tion.16 21 26 33 34 This is largely down to the previous
studies either being inadequately powered with smaller
study sizes (cohorts range from 32 to 1064 included
patients), from single site studies, or a study that
includes all minor head injury regardless of anticoagula-
tion status with subgroup analysis of anticoagulated
patients.
The majority of international guidance on the man-
agement of head injury does not advise speciﬁcally on
the care of patients who are anticoagulated mainly due
to the lack of sufﬁciently powered studies to address
management in such a subpopulation.9 12 Guidance
from NICE2 6 has changed based on the review of a
number of studies judged by NICE to be of low quality.
As a result, the current guidance recommends a CT scan
for all anticoagulated patients within 8 hours of suffering
a head injury regardless of the presence of any other
indication for a scan. This would signiﬁcantly increase
workload and costs for hospitals. Equally the National
Emergency X-Radiology Utilisation Study (NEXUS II),
CT in Head Injury Patients (CHIP), American College
of Emergency Physicians (ACEP) head CT and the
European Federation of Neurological Societies (EFNS)
advocate that all patients taking warfarin should have an
immediate CT scan irrespective of injury severity, GCS or
neurological symptoms.10–13 Guidance from SIGN
recommends admission to hospital for these patients,
but interestingly, not a CT scan.8 It is unclear what evi-
dence this guidance is based on. Guidance for the man-
agement of non-anticoagulated head injuries has
demonstrated the value of including clinical features
when deciding whether to investigate patients.
This study has shown that (1) head injury symptoms
and GCS can be used to predict adverse outcome in
anticoagulated patients suffering blunt head trauma, (2)
INR does not predict adverse outcome in those patients
with GCS=15, (3) patients with GCS=15 and no symp-
toms have a low risk of adverse outcome regardless of
INR (2.7%). Therefore, use of CT scanning in low-risk
patients may be of limited value, but the decision to rec-
ommend CT scanning in guidance should take into
account the potential beneﬁts, harms and costs of CT
scanning. Furthermore, our estimate of the low risk of
adverse outcome in those with GCS=15 and no symp-
toms needs to be conﬁrmed in other cohorts.
Further research is therefore needed to validate our
ﬁndings on a separate cohort of anticoagulated patients,
while decision analysis modelling is required to compare
the potential beneﬁts, harms and costs of CT scanning
in low-risk patients. In addition, further work is needed
on the newer oral anticoagulants and antiplatelet drugs
in order to inform clinical practice.
LIMITATIONS
The study was limited by not having a gold standard ref-
erence test for adverse outcome. For pragmatic reasons,
we undertook this observational study applying a range
of adverse outcomes. It is possible that a small number
of adverse outcomes would have been missed, although
every effort was made by the study team to ensure this
did not happen. Patients with an adverse outcome may
have been missed if they had died in the community or
attended another hospital with a delayed complication
thereby underestimating the proportion of adverse out-
comes in the study. The data collection process was
developed locally to suit each service model and as such,
the study was partially compromised by having some
data items missing. A strategy was employed throughout
the study to try to minimise missing data and improve
accuracy, as well as undertaking follow-up with each hos-
pital site up to 10 weeks after patient attendance as
recommended by Gilbert et al,29 when using medical
records. The missing items mainly included recording
the symptoms of amnesia and headache which we found
were far less likely to be documented than the symptoms
of vomiting and loss of consciousness. It is likely that
clinicians were less inclined to record amnesia and head-
ache as these are symptoms that cannot readily be
observed, and can be subject to uncertainty especially in
older patients with cognitive impairment. However, our
analysis included an extensive missing data analysis
which increased our conﬁdence in the study ﬁndings.
Acknowledgements The authors thank Rosemary Harper for her contribution
as a patient representative throughout the duration of the study; all the
Box 1 Adverse event rate by Glasgow Coma Scale (GCS)
and neurological symptoms
▸ GCS=15 and no neurological symptoms (n=2243): adverse
event=2.8% (n=65)
▸ GCS=15 and one neurological symptom (n=384): adverse
event=9.0% (n=38)
▸ GCS=15 and two neurological symptoms (n=109): adverse
event=13.5% (n=17)
▸ GCS=15 and three neurological symptoms (n=15): adverse
event=26.7% (n=4)
▸ GCS<15 (n=358): adverse event=20.9% (n=75)
Mason S, et al. BMJ Open 2017;7:e014324. doi:10.1136/bmjopen-2016-014324 7
Open Access
clinicians and research staff in the participating hospital sites who identified
patients in this study, without whose hard work this study would not have
been possible.
Contributors All authors made substantial contributions to the conception
and design (SM, SG, SR, FM), acquisition of the data (MK), or analysis and
interpretation (MDT, MK, MS, SG, SM, JR). MK drafted the article and all
other authors revised it critically for important intellectual content. SM is the
guarantor. All authors had full access to all of the data in the study and can
take responsibility for the integrity of the data and the accuracy of the data
analysis.
Funding This paper presents independent research commissioned by the
National Institute for Health Research (NIHR) under its Research for Patient
Benefit (RfPB) Programme grant reference number PB-PG-0808-17148.
Disclaimer The views expressed are those of the author(s) and not
necessarily those of the NHS, the NIHR or the Department of Health.
Competing interests None declared.
Ethics approval NRES Committee Yorkshire and The Humber—Sheffield:
11/H1308/13.
Provenance and peer review Not commissioned; externally peer reviewed.
Data sharing statement No additional data are available.
Open Access This is an Open Access article distributed in accordance with
the terms of the Creative Commons Attribution (CC BY 4.0) license, which
permits others to distribute, remix, adapt and build upon this work, for
commercial use, provided the original work is properly cited. See: http://
creativecommons.org/licenses/by/4.0/
REFERENCES
1. Kay A, Teasdale G. Head injury in the United Kingdom. World
J Surg 2001;25:1210–20.
2. National Institute for Health and Care Excellence. Head injury:
triage, assessment, investigation and early management of head
injury in infants, children and adults. (Clinical Guideline 176).
London. 2014. http://www.nice.org.uk/CG176
3. The Information Centre for Health and Social Care. Accident and
emergency attendances in England—2011-12, Experimental
Statistics, Table 14: Number of A&E attendances for 2011–12, First
A&E diagnosis “Head injury”. London. 2015. http://www.hscic.gov.uk/
searchcatalogue?productid=10477&q=title%3a%22Accident+and
+Emergency+Attendances+in+England%22&sort=Relevance&size=
10&page=1#top (accessed Dec 2015).
4. Rutland-Brown W, Langlois JA, Thomas KE, et al. Incidence of
traumatic brain injury in the United States, 2003. J Head Trauma
Rehabil 2006;21:544–8.
5. National Institute for Health and Care Excellence. Anticoagulation
Therapy commissioning guide (CG76). NICE, London. 2013. https://
www.nice.org.uk/guidance/cg76/resources/guide-for-commissioners-
anticoagulation-therapy-328998097861.
6. National Institute for Health and Care Excellence. Head injury:
triage, assessment, investigation and early management of head
injury in infants, children and adults. (Clinical Guideline 56.) London.
2007. http://www.nice.org.uk/CG56
7. Leiblich A, Mason S. Emergency management of minor head injury
in anticoagulated patients. Emerg Med J 2011;28:115–18.
8. The College Scottish Intercollegiate Guidelines Network. Early
management of patients with a head injury. (SIGN Guideline No
110). SIGN, 2009.
9. Stiell IG, Wells GA, Vandemheen K, et al. The Canadian CT head
rule for patients with minor head injury. Lancet 2001;357:1391–6.
10. Jagoda AS, Bazarian JJ, Bruns JJ Jr, et al. Clinical policy:
neuroimaging and decision making in adult mild traumatic brain
injury in the acute setting. Ann Emerg Med 2008;52:714–48.
11. Vos PE, Alekseenko Y, Battistin L, et al. Mild traumatic brain injury.
Eur J Neurol 2012;19:191–8.
12. Smits M, Dippel DWJ, Steyerberg EW, et al. Predicting intracranial
traumatic findings on computed tomography in patients with minor
head injury: the CHIP Prediction Rule. Ann Intern Med
2007;146:397–405.
13. Mower WR, Hoffman JR, Herbert M, et al. Developing a decision
instrument to guide computed tomographic imaging of blunt head
injury patients. J Trauma 2005;59:954–9.
14. New Zealand Guidelines Group. Traumatic brain injury: diagnosis,
acute management and rehabilitation. New Zealand, 2006. (NZGG).
http://www.acc.co.nz/PRD_EXT_CSMP/groups/external_
communications/documents/guide/wim2_059414.pdf.
15. Barbosa RR, Jawa R, Watters JM, et al. Evaluation and
management of mild traumatic brain injury. J Trauma Acute Care
Surg 2012;73:S307–14.
16. Fabbri A, Vandelli A, Servadei F, et al. Coagulopathy and NICE
recommendations for patients with mild head injury. J Neurol
Neurosurg Psychiatry 2004;75:1787–8.
17. Nishijima DK, Offerman SR, Ballard DW, et al. Immediate and
delayed traumatic intracranial hemorrhage in patients with head
trauma and preinjury warfarin or clopidogrel use. Ann Emerg Med
2012;59:460–8.e7.
18. Nishijima DK, Offerman SR, Ballard DW, et al. Risk of traumatic
intracranial hemorrhage in patients with head injury and preinjury
warfarin or clopidogrel use. Acad Emerg Med 2013;20:140–5.
19. Peck KA, Sise CB, Shackford SR, et al. Delayed intracranial
hemorrhage after blunt trauma: are patients on preinjury
anticoagulants and prescription antiplatelet agents at risk? J Trauma
Inj Infect Crit Care 2011;71:1600–4.
20. Riccardi A, Frumento F, Guiddo G, et al. Minor head injury in the
elderly at very low risk: a retrospective study of 6 years in an
Emergency Department (ED). Am J Emerg Med 2012;31:37–41.
21. Menditto VG, Lucci M, Polonara S, et al. Management of minor head
injury in patients receiving oral anticoagulant therapy: a prospective
study of a 24-hour observation protocol. Ann Emerg Med
2012;59:451–5.
22. Claudia C, Claudia R, Agostino O, et al. Minor head injury in
warfarinized patients: indicators of risk for intracranial hemorrhage.
J Trauma 2011;70:906–9.
23. Rendell S, Batchelor JS. An analysis of predictive markers for
intracranial haemorrhage in warfarinised head injury patients. Emerg
Med J 2012;30:28–31.
24. Hanlon D. An evidence-based approach to managing the
anticoagulated patient in the emergency department. Emerg Med
Pract 2011;13:1–19. quiz 19.
25. Li J, Brown J, Levine M. Mild head injury, anticoagulants, and risk of
intracranial injury. Lancet 2001;357:771–2.
26. Gittleman AM, Ortiz AO, Keating DP, et al. Indications for CT in
patients receiving anticoagulation after head trauma. AJNR Am
J Neuroradiol 2005;26:603–6.
27. Lavoie A, Ratte S, Clas D, et al. Preinjury warfarin use among
elderly patients with closed head injuries in a trauma center.
J Trauma 2004;56:802–7.
28. Morris F, Wardrope J, Ramlakhan S. Minor injury and illness at a
glance. Sheffield: Wiley Blackwell, 2014:25.
29. Gilbert EH, Lowenstein SR, Koziol-McLain J, et al. Chart reviews in
emergency medicine research: Where are the methods? Ann Emerg
Med 1996;27:305–8.
30. Hayes AF, Krippendorff K. Answering the call for a standard
reliability measure for coding. Commun Methods Meas
2007;1:77–89.
31. Rubin DB. Multiple imputation after 18+ years. J Am Stat Assoc
1996;91:473–89.
32. Keeling D, Baglin T, Tait C, et al. Guidelines on oral anticoagulation
with warfarin—fourth edition. Br J Haematol 2011;154:311–24.
33. Reynolds FD, Dietz PA, Higgins D, et al. Time to deterioration of the
elderly, anticoagulated, minor head injury patient who presents
without evidence of neurologic abnormality. J Trauma
2003;54:492–6.
34. Batchelor JS, Ahmed S. A meta-analysis to determine the effect of
pre-injury warfarin on mortality in trauma patients. J Trauma
2014;16:108–13.
8 Mason S, et al. BMJ Open 2017;7:e014324. doi:10.1136/bmjopen-2016-014324
Open Access
